|
|
SPOT ON
|
|
DPP-4 inhibitors - clinical benefit still unproven
|
|
|
NEW ON THE MARKET
|
|
Lisdexamfetamine (ELVANSE) as second-line therapy for treatment-refractory attention deficit hyperactivity disorder?
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Vaccination against rotavirus for all infants?
|
|
|
a-t READERS' QUESTIONS AND COMMENTS
|
|
Which contraceptive to use after venous thromboembolism?
Opioid substitution: is levomethadone (L-POLAMIDON) safer than methadone (e.g. METHADDICT)?
|
|
|
IN BRIEF
|
|
Enough: 30 years of flunitrazepam (ROHYPNOL, generics) |
|
|
CURRENT ADR NETWORK REPORT
|
|
Angioedema with ALMASED powder
|
|
|
SIDE EFFECTS
|
|
Progressive multifocal leukoencephalopathy (PML) with fingolimod (GILENYA)
Promotion of quinine (LIMPTAR N) against leg cramps
New warnings and contraindications for mefloquine
|
|
|
e a-t IN INTERNET
|
|
Anaphylactic reactions with chlorhexidine (e.g. CHLORHEXAMED)
|
|